Cargando…

Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report

BACKGROUND: Given the complex nature of symptom presentation and medication regimens, psychiatric clinics may benefit from additional tools to personalize treatments. Utilizing pharmacogenetic information may be helpful in assessing unique responses to therapy. We report herein a case of wearing-off...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eum, Seenae, Schneiderhan, Mark E., Brown, Jacob T., Lee, Adam M., Bishop, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496345/ https://www.ncbi.nlm.nih.gov/pubmed/28673279 http://dx.doi.org/10.1186/s12888-017-1396-x

Ejemplares similares

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
por: Eum, Seenae, et al.
Publicado: (2016)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis
por: Lopez, P. Gil, et al.
Publicado: (2021)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman, Phyllis M, et al.
Publicado: (2017)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022)

S206. ARIPIPRAZOLE LONG-ACTING INJECTABLE IN SCHIZOPHRENIA DURING PREGNANCY: A CASE REPORT
por: Sole, Eva, et al.
Publicado: (2020)

Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report
por: Fernández-Abascal, Blanca, et al.
Publicado: (2021)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
por: Hard, Marjie L., et al.
Publicado: (2019)

Aripiprazole monotherapy in an adolescent worsens psychosis
por: Panigrahi, Mahima, et al.
Publicado: (2013)

Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)
por: Moleon, A., et al.
Publicado: (2023)

Pharmacogenetics of cancer therapy: breakthroughs from beyond?
por: Lu, Da-Yong, et al.
Publicado: (2015)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
por: Maini, Kunal, et al.
Publicado: (2021)

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
por: Ballester-Gracia, Isabel, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
por: Biagi, Enrico, et al.
Publicado: (2017)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison
por: Harlin, Matthew, et al.
Publicado: (2023)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
por: Madhusoodanan, Subramanian, et al.
Publicado: (2008)

Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management
por: Brown, Jacob T., et al.
Publicado: (2020)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
por: Lian, Lulu, et al.
Publicado: (2022)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza, Vanessa, et al.
Publicado: (2018)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Comment on “Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison” [Letter]
por: Rege, Bhaskar, et al.
Publicado: (2023)

Alternative starting regimen with aripiprazole long-acting treatments, a case report
por: Huete Naval, M., et al.
Publicado: (2022)

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
por: Hard, Marjie L., et al.
Publicado: (2018)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: A case report
por: Kurata, Tsutomu, et al.
Publicado: (2019)

S200. COMPARISON BETWEEN LONG-ACTING INJECTABLE ARIPIPRAZOLE VERSUS PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA: SYSTEMATIC REVIEW AND INDIRECT TREATMENT COMPARISON
Publicado: (2020)

Pharmacogenetics of SSRIs and Sexual Dysfunction
por: Osis, Liana, et al.
Publicado: (2010)

Utilizing pharmacogenetics when treating first episode psychosis
por: Korchia, Theo, et al.
Publicado: (2023)

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia
por: Singh, Arun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g4sdhc45hlie2ld0rikijicpq8